Diagnosis, classification and treatment of gestational trophoblastic neoplasia

被引：34

作者：

Biscaro, Andressa ^{[1
]}

Braga, Antonio ^{[2
,3
]}

Berkowitz, Ross Stuart ^{[4
,5
]}

机构：

[1] Univ Fed Fluminense, Maternal & Child Hlth, Rio De Janeiro, RJ, Brazil

[2] Univ Fed Rio de Janeiro, Rio De Janeiro, RJ, Brazil

[3] Univ Fed Fluminense, Rio De Janeiro, RJ, Brazil

[4] Harvard Med Sch, Dept Obstet Gynecol & Reprod Biol, Boston, MA USA

[5] Brigham & Womens Hosp, Harvard Med Sch, Boston, MA USA

来源：

REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA | 2015年 / 37卷 / 01期

关键词：

Gestational trophoblastic disease/diagnosis; Gestational trophoblastic disease/classification; Gestational trophoblastic disease/drug therapy; Choriocarcinoma/drug therapy;

D O I：

10.1590/SO100-720320140005198

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Gestational trophoblastic neoplasia (GTN) is the term to describe a set of malignant placental diseases, including invasive mole, choriocarcinoma, placental site trophoblastic tumor and epithelioid trophoblastic tumor. Both invasive mole and choriocarcinoma respond well to chemotherapy, and cure rates are greater than 90%. Since the advent of chemotherapy, low-risk GTN has been treated with a single agent, usually methotrexate or actinomycin D. Cases of high-risk GTN, however, should be treated with multiagent chemotherapy, and the regimen usually selected is EMA-CO, which combines etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine. This study reviews the literature about GTN to discuss current knowledge about its diagnosis and treatment.

引用

页码：42 / 51

页数：10

共 52 条

[31] Maesta I, 2012, REV BRAS GINECOL OBS, V34, P143, DOI 10.1590/S0100-72032012000400001
[32] Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen
Mao, Yuyan
Wan, Xiaoyun
Lv, Weiguo
Xie, Xing
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2007, 98 (01) : 44 - 47
[33] The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l-1
McGrath, S.
Short, D.
Harvey, R.
Schmid, P.
Savage, P. M.
Seckl, M. J.
[J]. BRITISH JOURNAL OF CANCER, 2010, 102 (05) : 810 - 814
[34] Comparison of pulsed actinomycin D versus 5-day methotrexate for the treatment of low-risk gestational trophoblastic disease
Mousavi, Azamsadat
Cheraghi, Fatemeh
Yarandi, Fariba
Gilani, Mitra Modaress
Shojaei, Hadi
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2012, 116 (01) : 39 - 42
[35] Ngan HYS, 2002, INT J GYNECOL OBSTET, V77, P285
[36] Ngu SF, 2014, CURR OBSTET GYNECOL, V3, P84, DOI 10.1007/s13669-013-0071-6
[37] Gestational Trophoblastic Neoplasia
Osborne, R.
Dodge, J.
[J]. OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2012, 39 (02) : 195 - +
[38] Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study
Osborne, Raymond J.
Filiaci, Virginia
Schink, Julian C.
Mannel, Robert S.
Secord, Angeles Alvarez
Kelley, Joseph L.
Provencher, Diane
Miller, David Scott
Covens, Allan L.
Lage, Janice M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) : 825 - 831
[39] The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease
Pezeshki, M
Hancock, BW
Silcocks, P
Everard, JE
Coleman, J
Gillespie, AM
Tidy, J
Coleman, RE
[J]. GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 423 - 429
[40] A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia
Powles, T.
Savage, P. M.
Stebbing, J.
Short, D.
Young, A.
Bower, M.
Pappin, C.
Schmid, P.
Seckl, M. J.
[J]. BRITISH JOURNAL OF CANCER, 2007, 96 (05) : 732 - 737

← 1 2 3 4 5 6 →